文献速递慢性肾脏病

评估CKD患者选择性抗氧化防御的药理学「应激试验」

A Pharmacologic "Stress Test" for Assessing Select Antioxidant Defenses in Patients with CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-04-14

该研究在18名健康志愿者和24例3-4期CKD患者中单次注射锡原卟啉(SnPP),观察血浆和尿抗氧化蛋白变化及肾脏安全性。结果显示SnPP可安全给药,并诱导HO-1、NQO1、铁蛋白和p21呈剂量和时间依赖性升高,但CKD患者对低剂量SnPP的HO-1反应和高剂量SnPP的p21反应显著受抑。

要点

  • SnPP单次注射可安全用于健康人和3-4期CKD患者,未见肾毒性证据。
  • SnPP可诱导血浆HO-1、NQO1、铁蛋白和p21呈剂量和时间依赖性升高。
  • CKD患者对SnPP的HO-1和p21反应显著低于健康志愿者。

核心结论

  • SnPP可安全给药,其诱导的HO-1、NQO1、铁蛋白和p21变化可反映抗氧化基因反应性/储备。

研究设计与样本

  • 18名健康志愿者和24例3-4期CKD患者(3期12例,eGFR 30-59 ml/min per 1.73 m2;4期12例,eGFR 15-29 ml/min per 1.73 m2)单次注射SnPP 9、27或90 mg,随访至给药后4天。

主要发现

  • CKD患者基线血浆HO-1、铁蛋白、p21和NQO1均升高。
  • 血浆HO-1和尿NQO1水平与eGFR呈负相关(r=-0.85至-0.95)。
  • SnPP注射后四种蛋白均呈统计学显著的剂量和时间依赖性升高,但个体间差异明显。
  • CKD患者对高剂量SnPP的p21反应和对低剂量SnPP的HO-1反应显著低于健康志愿者。
  • SnPP耐受良好,未观察到肾毒性证据。

关键数值与推荐

  • CKD分期标准:3期eGFR 30-59 ml/min per 1.73 m2,4期eGFR 15-29 ml/min per 1.73 m2。
  • SnPP给药剂量为9、27或90 mg单次注射。

临床怎么用

  • SnPP药理学应激试验可用于评估CKD患者抗氧化基因反应性和储备,但需注意个体差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Oxidative stress is a hallmark and mediator of CKD. Diminished antioxidant defenses are thought to be partly responsible. However, there is currently no way to prospectively assess antioxidant defenses in humans. Tin protoporphyrin (SnPP) induces mild, transient oxidant stress in mice, triggering increased expression of select antioxidant proteins (e.g., heme oxygenase 1 [HO-1], NAD[P]H dehydrogenase [quinone] 1 [NQO1], ferritin, p21). Hence, we tested the hypothesis that SnPP can also variably increase these proteins in humans and can thus serve as a pharmacologic "stress test" for gauging gene responsiveness and antioxidant reserves. DESIGN: , setting, participants, & measurementsA total of 18 healthy volunteers and 24 participants with stage 3 CKD (n=12; eGFR 30-59 ml/min per 1.73 m2) or stage 4 CKD (n=12; eGFR 15-29 ml/min per 1.73 m2) were injected once with SnPP (9, 27, or 90 mg). Plasma and/or urinary antioxidant proteins were measured at baseline and for up to 4 days post-SnPP dosing. Kidney safety was gauged by serial measurements of BUN, creatinine, eGFR, albuminuria, and four urinary AKI biomarkers (kidney injury molecule 1, neutrophil gelatinase-associated lipocalin, cystatin C, and N-acetyl glucosaminidase). RESULTS: Plasma HO-1, ferritin, p21, and NQO1 were all elevated at baseline in CKD participants. Plasma HO-1 and urine NQO1 levels each inversely correlated with eGFR (r=-0.85 to -0.95). All four proteins manifested statistically significant dose- and time-dependent elevations after SnPP injection. However, marked intersubject differences were observed. p21 responses to high-dose SnPP and HO-1 responses to low-dose SnPP were significantly suppressed in participants with CKD versus healthy volunteers. SnPP was well tolerated by all participants, and no evidence of nephrotoxicity was observed. CONCLUSIONS: SnPP can be safely administered and, after its injection, the resulting changes in plasma HO-1, NQO1, ferritin, and p21 concentrations can provide information as to antioxidant gene responsiveness/reserves in subjects with and without kidney disease. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Study with RBT-1, in Healthy Volunteers and Subjects with Stage 3-4 Chronic Kidney Disease, NCT0363002 and NCT03893799.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zager RA, Johnson ACM, Guillem A, et al. A Pharmacologic "Stress Test" for Assessing Select Antioxidant Defenses in Patients with CKD. Clin J Am Soc Nephrol. 2020. PMID: 32291269. doi:10.2215/CJN.15951219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。